The objective of this study was prospectively to investigate the health-related quality of life (HRQOL) of 80 pediatric recipients of allo-SCT for malignant and non-malignant diseases. The PedsQL 4.0 was used to assess self-reported physical, emotional and social functioning of children X5 years old once, pre-allo-SCT and on days þ 100, þ 180, þ 365 and þ 730. Emotional and social functioning was stable pre-to-post-allo-SCT and comparable to the normative sample (P40.05), and physical functioning was 17 points lower pre-allo-SCT (Pp0.01) with improved scores equivalent to the norms by day þ 730. Lower physical scores were reflected by 50-54% of children reporting difficulties with movement, strength, pain and fatigue. At baseline, children ages 5-7 reported lower social functioning (Po0.05) and patients with non-malignant disease reported better physical functioning (Po0.05). Emotional functioning in ages 8-12 improved over time (Po0.05). More than 50% of the participants were minority and their HRQOL was similar to non-minority participants. Physical functioning significantly improved for recipients of reduced-toxicity conditioning (Pp0.01), significantly worsened for patients with chronic GVHD (cGVHD; Po0.05), and significantly decreased in recipients of matched-unrelated donor transplant who developed cGVHD (Po0.05). Multidisciplinary efforts are necessary to identify and support pediatric patients' physical needs to improve functional outcomes.
INTRODUCTION
Hematopoietic SCT (HSCT) is a potentially curative therapy for children with hematological malignancies, solid tumors, immunodeficiency diseases and metabolic disorders. 1 Advanced techniques in tissue typing, better understanding of the immune system and biological response modifiers, and better supportive care, [2] [3] [4] along with the use of unrelated or mismatched-related donors and peripheral blood stem cells or umbilical cord blood stem cells have contributed to improved patient outcomes. [5] [6] [7] [8] Furthermore, to improve survival [5] [6] [7] [8] and reduce acute complications such as acute GVHD (aGVHD) and late effect including organ toxicity, there has been a shift from treating pediatric patients with myeloablative conditioning (MAC) to reduced-toxicity conditioning (RTC) followed by allo-SCT. 9 Although HSCT is well-established, markedly less attention has focused on the health-related quality of life (HRQOL) of pediatric recipients. Results from cross-sectional studies indicate worse HRQOL early in the post transplant period, for unrelated transplant compared with autologous-or allogeneic-related transplants, and for patients with chronic GVHD (cGVHD). 10 In addition, significant HRQOL time trends have been reported for recipients of unrelated donor transplants with peak declines between baseline to 3 months 11 and worsening trajectories for older children. 12 Moreover, a majority of HRQOL studies focus on overall wellbeing and few empirical adult and pediatric studies have addressed the degree to which HSCT impacts specific indicators of HRQOL, such as physical and psychosocial functioning. Limitations in physical function have been reported for childhood HSCT survivors ranging from 7% (clinician report) 13 to 17% (selfreport) 14 and 40-62% from direct measures of cardiopulmonary fitness. 15 Associations between poor physical performance and cGVHD, cardiac conditions, immune suppression, treatment for secondary malignancies 16 and myeloid disease 17 have been found. Reports of psychological functioning are mixed. Some studies support that patients with higher levels of distress pretransplant tend to experience higher levels of distress following stem cell infusion, suggesting that pre-HSCT psychological state may predict post-HSCT distress and functioning. [18] [19] [20] [21] [22] [23] [24] Others claim that pediatric survivors have reasonable adjustment and satisfactory HRQOL the first 2 years post-HSCT, [25] [26] [27] whereas further studies suggest that pediatric HSCT recipients are at risk for developing long-term emotional or social problems. 28, 29 Based on limited prospective longitudinal studies, it is difficult for investigators to accurately identify decrements to HRQOL. The objective of this study was to describe the longitudinal HRQOL of pediatric allo-SCT recipients to identify demographic, diseasespecific and treatment-related factors that may impact physical and psychosocial functioning.
MATERIALS AND METHODS Eligibility
The sample consisted of pediatric recipients X5 years of age undergoing allo-SCT at Columbia University Medical Center (CUMC) between November 2002 and December 2008. Eighty patients received protocoldriven treatment regimens based on their primary disease and HRQOL was included as an exploratory objective. Research approval was received from CUMC's Institutional Review Board and all parents and patients gave written informed consent and assent when applicable.
Conditioning regimens
Preparative therapy consisted of either MAC or RTC regimens. A majority of the MAC regimens contained either TBI (12 Gy) without lung shielding or BU (12.8 mg/kg for patients 44 years old) in combination with melphalan (135 mg/m 2 ) or cyclophosphamide. As previously described, 7, 8 all RTC regimens were fludarabine-based (150-180 mg/m 2 ) and patients either received fludarabine/BU or fludarabine/cyclophosphamide. Previously described prophylactic treatment for aGVHD, 30, 31 consisted of tacrolimus (0.03 mg/kg/day continuous i.v. infusion or 0.12 mg/kg orally twice daily) adjusted to maintain blood levels between 5 and 20 ng/mL on day 1 of conditioning or day À 1 pre-allo-SCT, as well as mycophenolate mofetil administered at 15-30 mg/kg q6-12 h starting day þ 1 post-allo-SCT. 30, 31 GVHD grading was according to the Seattle Consensus Criteria. 32 Evaluation of patient-reported HRQOL The PedsQL 4.0 Generic Core Scale is a valid and reliable measure of HRQOL for children with chronic health conditions [33] [34] [35] and has been used in pediatric HSCT studies. [36] [37] [38] [39] [40] HRQOL was assessed using the child selfreported version. The instrument consists of 23 items that measure physical (8 items), emotional (5 items), social (5 items) and school functioning (5 items). Self-report for ages 8-18 þ utilizes a five-point Likert type response format, whereas the young child self-report for ages 5-7 uses a three-point response scale. 41, 42 Assessments were collected by a senior pediatric psychologist (SAS) once pre-allo-SCT (baseline) and on days þ 100, þ 180, þ 365 and þ 730 post transplantation.
Statistical analysis
Total scores from the physical, emotional and social functioning domains were the dependent variables of interest. The school functioning domain was excluded, because children stopped attending school during the acute stage of treatment and a large proportion of missing answers were expected and found for this sub-scale. As there were no differences by language, the US English (n ¼ 70) and Spanish (n ¼ 10) versions were combined to yield a total score for each domain. Items were reversed scored and linearly transformed to a scale of 0-100, with higher scores indicating better HRQOL (that is, fewer symptoms). 35 All analyses were exploratory and no adjustments were made to the alpha level (Po0.05 was significant). Data were analyzed using software packages SPSS 18 (IBM SPSS Inc., Chicago, IL, USA) and HLM 7. Baseline. One-sample t-tests and effect sizes (ESs) were used to compare subjects with a normative sample. ESs were calculated using the pooled s. Longitudinal data. Changes from baseline were assessed using paired sample t-tests and the reliable change index. The reliable change index 45 was calculated by subtracting the post-allo-SCT score from the pre-allo-SCT score and dividing by the s.e. of the difference, which is derived from the s.e. of measurement (s.e.m.). The s.e.m. is considered a stable method for determining clinically significant change in varying samples 46 and clinically significant individual change. 47 Hierarchical linear models (HLM) were constructed to test for group differences and change from baseline using restricted maximum likelihood estimators. Unlike traditional repeated-measures techniques, mixed analysis of variance or multivariate analysis of variance, which require complete data and identical spacing between measurement occasions, HLM uses all available data and can account for missing and miss-timed data, [48] [49] [50] thereby providing less biased treatment effects. 51 This is an important distinction for intent-to-treat approaches where missing/misstimed data are expected. Questionnaires were coded according to their corresponding time point and treated categorically in these analyses.
The time variable was recoded to 0, 3.33, 6, 12.17 and 24.33 so that estimates reflected the change in months rather than days. Only linear models were investigated as quadratic models were nonsignificant. Models were constructed using a forward stepwise entry method to assess the associations between the sub-scales and demographic variables, diseasespecific indicators and treatment-related GVHD. Blocks of independent variables were entered into the models as follows: (1) demographic characteristics (age, gender and race); (2) disease-specific variable (diagnosis type); and (3) treatment-specific variables (conditioning regimen and GVHD). Age was grouped similarly to the PedsQL 4.0 assessments (that is, ages 5-7, 8-12 and 13-18 þ ). A difference in HLM trajectories indicate a difference between groups at the end of the study. 52 To describe the magnitude of the difference in scores between select groups at 2 years post-allo-SCT and provide clinical context to these data, ESs were calculated using model-based coefficients. End-of-study ESs do not compare raw means between groups but the degree to which the mean difference is greater at 2 years than at baseline and should be viewed descriptively.
Longitudinal patterns were also evaluated by examining the frequency of clinically significant changes using the minimally important difference. The minimally important difference represents the smallest score difference that is clinically significant and thus likely to be meaningful to patients and clinicians. Previously identified minimally important differences for the PedsQL 4.0 are 6.66 (physical functioning), 8 .94 (emotional functioning) and 8.36 (social functioning). 34 
RESULTS

Basic study characteristics
Patient characteristics are presented in Table 1 . The median age at allo-SCT was 12.82 years (range ¼ 4.44-23.12), 57 (65%) were male, 55 (69%) were minority and 29 (36%) had died because of disease progression or treatment-related complications. A total of 47 participants (59%) were diagnosed with a malignant disease, of which 44 (94%) were diagnosed with a hematological malignancy. The remaining 33 participants were diagnosed with a benign hematologic disorder, the most prevalent was severe aplastic anemia (45%) followed by sickle cell disease (36%). MAC was given to 43 patients (54%), whereas 37 patients received RTC.
Sub-scale completion rates at baseline were: physical functioning, 74 (93%), emotional functioning, 75 (94%) and social functioning, 74 (93%). Of the patients who provided baseline scores, completion rates at days þ 100, þ 180, þ 365 and þ 730 for physical and emotional functioning were 46, 51, 31 and 19, and for social functioning 46, 49, 30 and 19, respectively. Cronbach's alpha values across time points ranged from 0.75 to 0.87 (physical functioning), 0.71 to 0.84 (emotional functioning) and 0.62 to 0.79 (social functioning).
Child self-reported HRQOL outcomes Baseline. Sub-scale scores did not differ between survivors and non-survivors and scores were representative of the study population and did not reflect only children who were functioning relatively well. Baseline scores compared with the normative sample are detailed in Table 2 . Emotional and social functioning was not statistically significantly different from the normative sample. Children reported significantly worse physical functioning than the normative sample (mean difference ¼ À 17.09, t ¼ À 8.39, P ¼ 0.00; ES ¼ À 1.08). Table 3 presents the specific physical functioning areas patients reported difficulties with the highest expressions (50-54%) evidenced for running, exercise, strength, pain and fatigue.
Baseline HLM estimates indicate that age was only associated with social functioning with younger children (ages 5-7, M ¼ 73.81; t ¼ À 2.67; P ¼ 0.01) having greater difficulties than older children (ages [8] [9] [10] [11] [12] were a great deal worse (ES ¼ À 1.31) at 2 years post treatment, whereas the magnitude of the difference between cGVHD (M ¼ 42.72) and no GVHD (M ¼ 83.96) was large (ES ¼ À 3.34). Furthermore, a significant decline in physical functioning was evidenced for MUD recipients with cGVHD (n ¼ 8; slope ¼ À 0.79; t ¼ À 2.39; P ¼ 0.02) compared with matched-related donor recipients with cGVHD (slope ¼ À 0.10; Figure 2c ). The magnitude of the difference at 2 years was large (ES ¼ À 1.00), with MUD recipients performing a great deal worse. Finally, no significant time trend was found for aGVHD (n ¼ 35) and any of the subscales. All other demographic, disease-specific and treatmentrelated characteristics were not significantly associated with time. Table 4 shows the percentage of patients who reported worsening, improvement or stable HRQOL ratings based on the minimally important difference at each time point relative to their own baseline. Over 30% of patients reported improved physical functioning and emotional functioning at each follow-up. This trend was also observed for social functioning with the exception of day þ 180. In the acute post-allo-SCT follow-up period (that is, day þ 100 and day þ 180), 30-35% of patients reported a decline in physical functioning and social functioning, whereas 24% of patients had declining emotional functioning values during the same time period. At 1-year post treatment, 37% reported worsening social functioning compared with 30% reporting improved and 33% reporting stable scores.
DISCUSSION
This study highlights the importance of including HRQOL as part of the treatment investigations to further define outcomes related to pediatric allo-SCT. Transplant providers should consider performance secondary to the curative potential of allo-SCT and not overestimate HRQOL. To help families make informed treatment decisions, including the clinical complications of therapy combined with possible changes in HRQOL especially physical functioning as part of the consent discussion will help ensure realistic expectations during treatment and for recovery following allo-SCT.
Strengths of this study include reporting HRQOL from the child's perspective, which is rare and this is the first series to have 450% minority participants. Encouragingly, no significant differences were found by race over the study period. One possible explanation is that enrollment in the New York State Children's Health Insurance Program, which has shown to reduce preexisting racial/ethnic disparities in health-care access, and improve continuity and quality of care for enrollees, 53 may have contributed to the larger number of minority subjects in this trial and nonsignificant differences. Nationally, as pediatric allo-SCT is increasingly being used as curative therapy and access to such programs improves, the implications of this finding will be important for future comparisons.
Emotional and social functioning was similar to the normative sample and remained stable over the 2-year study period, which is similar to previous reports indicating pediatric survivors are reasonably adapted the first 1-to-2 year's post-HSCT. [25] [26] [27] Although this is in contrast to other studies that found higher levels of distress before and post-HSCT, our findings support the notion that pre-transplant psychological state may predict post transplant behavior. [18] [19] [20] [21] [22] [23] [24] Our high psychosocial scores may reflect the level of emotional and social support received from their own family and friends as well as supportive relationships made with other children receiving care, clinical staff and providers. However, it is also possible that change may be very subtle and not easily detected or the PedsQL 4.0 was not sufficiently sensitive to detect emotional or social functioning perturbations and results should be interpreted with caution. Future studies would benefit from including additional measures to further define psychosocial outcomes.
In contrast, baseline physical functioning was impaired relative to the normative sample. Specifically, 50-54% of our patients indicated difficulties associated with running, exercise, strength, pain and fatigue at baseline. By day þ 365 there were mean positive changes in overall physical functioning with significant improvements equivalent to the normative sample evidenced at day þ 730, suggesting ameliorations in the indicators of physical functioning as the time from treatment increased. Identifying areas of difficulty before treatment may aid practitioners in selecting patients who require additional management. Through improved monitoring and support of physical needs, better functional outcomes may be achieved earlier in the postallo-SCT period.
Although individual classification of response to treatment revealed that the majority of patients self-reported stable or improved scores over the post-treatment period, approximately one-third of children reported clinically significant declines in physical functioning at days þ 100 and þ 180 and social functioning through day þ 365.
Demographic and disease-specific indicators were associated with mean differences at baseline, whereas a majority of the changes from baseline were associated with transplant-related characteristics. Specifically at baseline, younger children had significantly lower social functioning than children 8 years and older and patients with malignant disease had significantly lower physical functioning compared with patients with non-malignant diseases. Over time, children ages 8-12 had the least emotional difficulties, which is counter to a previous report supporting that younger age (o6 years) at transplant was associated with less emotional problems post transplant. 23 RTC was significantly associated with better overall physical functioning compared with MAC, which is consistent with two studies evaluating the HRQOL of adult patients undergoing allo-SCT after reducedintensity conditioning vs MAC. 54, 55 Children who developed cGVHD experienced significant declines in physical functioning, whereas children without GVHD improved comparable to previous studies of physical ability. 56, 57 Furthermore, physical functioning for patients with cGVHD who received MUD transplantation significantly deteriorated from baseline and patients with cGVHD who received matched-related donor stem cells remained unchanged.
There are several limitations to this study. In particular, data were collected from a single institution, and the sample size was small and further limited by missing data. Statistical power and the ability to identify other related factors was likely limited by the reduced sample that remained in the study. The data analyses were based on the assumption that missing data were missing at random. Although not recorded in detail, missing observations were encountered for several reasons including morbidity and mortality, scheduling and non-administration of questionnaires during clinic visits, unavailability of the patient because of returning to their local institution for follow-up care or noncompliance issues. Therefore, results should be viewed in light of these limitations and larger longitudinal samples are needed to confirm these findings.
Despite these limitations, results from this study provide a comprehensive longitudinal examination of HRQOL for pediatric allo-SCT recipients. Implications of these findings are important for treatment planning and providing intervention assistance for atrisk subgroups to achieve better performance earlier in the postallo-SCT period. Directions for future research include the establishment of larger multicenter studies to evaluate longerterm HRQOL outcomes to identify additional risk factors and interventions to support physical and psychosocial well-being. 
